| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/16/2006 | WO2006016602A1 Nateglinide-containing preparation reduced in bitterness |
| 02/16/2006 | WO2006016530A1 Transnasal composition having immediate action and high absorbability |
| 02/16/2006 | WO2006016468A1 Method of producing liposome-containing preparation |
| 02/16/2006 | WO2006016282A2 Media indexer |
| 02/16/2006 | WO2006016139A1 Composition for promoting vascular smooth muscle relaxation |
| 02/16/2006 | WO2006016078A1 Long-acting colloidal insulin formulation and preparation thereof |
| 02/16/2006 | WO2006016040A1 Compositions containing nicorandil, preparation method and use |
| 02/16/2006 | WO2005116068A8 Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities |
| 02/16/2006 | WO2005082423A3 Serum albumin conjugated to fluorescent substances for imaging |
| 02/16/2006 | WO2005055976A3 Powder containing low-molecular dextran and method for producing the same |
| 02/16/2006 | WO2005013897A3 Magnetic nanoparticle compositions, and methods related thereto |
| 02/16/2006 | WO2005005455A3 Specific human antibodies |
| 02/16/2006 | WO2004106359A3 Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals |
| 02/16/2006 | WO2004101600A3 Novel poly(ethylene glycol) modified compounds and uses thereof |
| 02/16/2006 | US20060036028 Solid phase synthesis using a solid support prepared by polymerization of a polyarylmethyl-protected alkoxylated styrene monomer that has 2-10 oxyalkylene units |
| 02/16/2006 | US20060035983 Methods for treating fungal infections |
| 02/16/2006 | US20060035973 Pharmaceutical composition for intracellular acidification with cis-urocanic |
| 02/16/2006 | US20060035924 Daily melatonin dosing units |
| 02/16/2006 | US20060035905 Formulations of phosphodiesterase 5 inhibitors and methods of use |
| 02/16/2006 | US20060035874 Pharmaceutical products and composition comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| 02/16/2006 | US20060035862 Tolerance of 4-(4-(2-pyrrolycarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration |
| 02/16/2006 | US20060035842 Ophthalmic composition |
| 02/16/2006 | US20060035839 Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments |
| 02/16/2006 | US20060035833 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035832 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035831 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035830 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035389 Immobilization of glycorproteins |
| 02/16/2006 | US20060035328 Artery-and vein-specific proteins and uses therefor |
| 02/16/2006 | US20060035325 Regulated apoptosis |
| 02/16/2006 | US20060034957 Vitamin-containing system for stabilising the immune response of animals |
| 02/16/2006 | US20060034932 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060034928 Tablet comprising cetirizine and pseudoephedrine |
| 02/16/2006 | US20060034926 Controlled release system |
| 02/16/2006 | US20060034917 Coating of tablet cores |
| 02/16/2006 | US20060034896 triglycerides such as triester of caprylic acid or capric acid with glycerin, used along with foods or drugs, without concerning about side effects and restrictive diets |
| 02/16/2006 | US20060034895 Supplement food for low blood glucose recovery |
| 02/16/2006 | US20060034894 Warming compositions and delivery systems therefor |
| 02/16/2006 | US20060034888 Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages |
| 02/16/2006 | US20060034869 Drug for treating liver diseases with the use of hollow protein nanoparticles |
| 02/16/2006 | US20060034865 Soluble MHC artificial antigen presenting cells |
| 02/16/2006 | US20060034863 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 02/16/2006 | US20060034858 A beta or an immunogenic fragment thereof presented by a virus or bacteria as part of an immunogenic composition effective to induce an immunogenic response comprising antibodies against A beta |
| 02/16/2006 | US20060034851 Targeted therapeutic delivery of vitamin D compounds |
| 02/16/2006 | US20060034842 Treating ErbB2-expressing breast cancer in a human by administering huMAb4D5-8 antibody and humanized 2C4 antibody variant 574 |
| 02/16/2006 | US20060034839 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
| 02/16/2006 | US20060034836 administering immunoglobulins linked to proteins having amino acid replacements in the amino acid sequence, to increase the circulating half-life in vivo than a corresponding antibody-based fusion proteins without amino acid replacements; reducing tumor size and metastasis in mammals |
| 02/16/2006 | US20060034827 Stabilized liquid anti-rsv antibody formulations |
| 02/16/2006 | US20060034824 Pharmaceutical composition comprising carriers for products |
| 02/16/2006 | US20060034822 Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eye |
| 02/16/2006 | US20060034816 comprises oxidoreductase enzyme in hydrated condition that catalyses conversion of atmospheric oxygen to hydrogen peroxide for transmittal through the dressing to the skin |
| 02/16/2006 | US20060034798 Water-in-oil emulsions with ethylene oxide groups, compositions, and methods |
| 02/16/2006 | US20060034797 Polymeric micromulsions |
| 02/16/2006 | US20060034775 Aerosol formulation for inhalation containing an anticholinergic |
| 02/16/2006 | US20060034759 Production and use of novel peptide-based agents with bispecific antibodies |
| 02/16/2006 | CA2573811A1 Stable particle formulations of erythropoietin receptor agonists |
| 02/16/2006 | CA2573668A1 Ophthalmic compositions and methods for treating ophthalmic conditions |
| 02/16/2006 | CA2573386A1 Composition for promoting vascular smooth muscle relaxation |
| 02/16/2006 | CA2572868A1 Long-acting colloidal insulin formulation and preparation thereof |
| 02/16/2006 | CA2570863A1 Compositions containing nicorandil, preparation method and use |
| 02/16/2006 | CA2570324A1 Rage fusion proteins and methods of use |
| 02/15/2006 | EP1625857A2 Conjugates of defined stoichiometry |
| 02/15/2006 | EP1625856A1 Hydrogel polymeric conjugates of a prodrug |
| 02/15/2006 | EP1625855A1 Polymeric prodrug with a self-immolative linker |
| 02/15/2006 | EP1625854A1 Albumin conjugates containing a glucuronic linker |
| 02/15/2006 | EP1625850A1 Immunostimulant |
| 02/15/2006 | EP1625845A1 Adhesive preparation containing fentanyl |
| 02/15/2006 | EP1625336A2 Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
| 02/15/2006 | EP1625335A2 Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| 02/15/2006 | EP1625334A2 Percussively ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| 02/15/2006 | EP1625149A2 Method and carrier complexes for delivering molecules to cells |
| 02/15/2006 | EP1624897A2 Hiv prodrugs cleavable by cd26 |
| 02/15/2006 | EP1624896A2 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances |
| 02/15/2006 | EP1624892A2 Therapeutic use of anti-cs1 antibodies |
| 02/15/2006 | EP1624891A2 Clotting factor-fc chimeric proteins to treat hemophilia |
| 02/15/2006 | EP1624884A2 Somatostatin vectors |
| 02/15/2006 | EP1624883A2 Compositions and methods related to production of erythropoietin |
| 02/15/2006 | EP1624870A2 Dosage form containing (s)-pantoprazole as active ingredient |
| 02/15/2006 | EP1624864A2 Controlled release of active agents utilizing repeat sequence protein polymers |
| 02/15/2006 | EP1624861A2 Novel topical steroid cream formulations |
| 02/15/2006 | EP1624855A2 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| 02/15/2006 | EP1624752A2 Delivery of compounds with rehydrated blood cells |
| 02/15/2006 | EP1481057B1 System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| 02/15/2006 | EP1412068B1 Emulsifier mixture |
| 02/15/2006 | EP1353629B1 Translucent nanoemulsion, production method, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields |
| 02/15/2006 | EP1267865B1 Amiodarone-containing parenteral solution |
| 02/15/2006 | EP1259562B1 Sterically hindered derivatives of water soluble polymers |
| 02/15/2006 | EP1198490B1 Neutral lipopolymer and liposomal compositions containing same |
| 02/15/2006 | EP1154767B1 Substituted stilbene compounds with vascular damaging activity |
| 02/15/2006 | EP1131054B1 Methods for preparing coated drug particles and pharmaceutical formulations thereof |
| 02/15/2006 | EP1010423B1 Oral pharmaceutical preparation comprising an antiulcer benzimidazole derivative, and process for its production |
| 02/15/2006 | EP1003550B1 Receptor specific transepithelial transport of therapeutics |
| 02/15/2006 | EP0998303B1 Polymer-drug conjugate for the treatment of cancer |
| 02/15/2006 | EP0762892B1 Diphtheria toxin vaccines bearing a mutated r domain |
| 02/15/2006 | CN1735624A Phospholipid derivatives and process for the production there |
| 02/15/2006 | CN1735435A Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 02/15/2006 | CN1735434A Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers |
| 02/15/2006 | CN1735418A Micelle assemblies |
| 02/15/2006 | CN1735413A High concentration formulations of opioids and opioid derivatives |
| 02/15/2006 | CN1735404A Medical devices employing novel polymers |